| 0.241 -0.002 (-0.82%) | 06-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.14  |
1-year : | 0.19 |
| Resists | First : | 0.12 |
Second : | 0.17 |
| Pivot price | 0.07  |
|||
| Supports | First : | 0.06 |
Second : | 0.05 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.07 |
| MA(100) : | 0.32 |
MA(250) : | 0.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 27.4 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 1.77 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PTE ] has closed above bottom band by 27.8%. Bollinger Bands are 81.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.09 - 0.09 | 0.09 - 0.09 |
| Low: | 0.07 - 0.07 | 0.07 - 0.07 |
| Close: | 0.07 - 0.07 | 0.07 - 0.07 |
PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Tue, 25 Apr 2023
PolarityTE, Inc. (PTE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Thu, 23 Mar 2023
When Can We Expect A Profit From PolarityTE, Inc. (NASDAQ:PTE)? - Yahoo Finance
Tue, 14 Mar 2023
Michael Brauser cancelled the acquisition of the remaining stake in PolarityTE, Inc.. - Marketscreener.com
Tue, 27 Dec 2022
PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company - PR Newswire
Mon, 16 May 2022
PolarityTE to Effectuate 1-for-25 Reverse Stock Split - PR Newswire
Fri, 13 May 2022
PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE® - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -47.8 |
| EBITDA (p.s.) | 172174 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|